Global RDC (Radionuclide Drug Conjugate) Services Market Growth (Status and Outlook) 2026-2032
Description
The global RDC (Radionuclide Drug Conjugate) Services market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
RDC (Radionuclide Drug Conjugate) services refer to professional services provided for the development, production and application of radionuclide drug conjugates. These conjugates usually combine radioisotopes with drugs (such as monoclonal antibodies, peptides or small molecules) to target specific cells or tissues for treatment, especially in cancer treatment. The main contents of RDC services include drug development, radionuclide labeling and screening, preclinical research (evaluation of drug conjugates), etc.
United States market for RDC (Radionuclide Drug Conjugate) Services is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for RDC (Radionuclide Drug Conjugate) Services is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for RDC (Radionuclide Drug Conjugate) Services is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key RDC (Radionuclide Drug Conjugate) Services players cover Rdcthera, Abzena, WuXi XDC, CD Formulation, CPC Scientific Inc, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LPI (LP Information)' newest research report, the “RDC (Radionuclide Drug Conjugate) Services Industry Forecast” looks at past sales and reviews total world RDC (Radionuclide Drug Conjugate) Services sales in 2025, providing a comprehensive analysis by region and market sector of projected RDC (Radionuclide Drug Conjugate) Services sales for 2026 through 2032. With RDC (Radionuclide Drug Conjugate) Services sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world RDC (Radionuclide Drug Conjugate) Services industry.
This Insight Report provides a comprehensive analysis of the global RDC (Radionuclide Drug Conjugate) Services landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on RDC (Radionuclide Drug Conjugate) Services portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global RDC (Radionuclide Drug Conjugate) Services market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for RDC (Radionuclide Drug Conjugate) Services and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global RDC (Radionuclide Drug Conjugate) Services.
This report presents a comprehensive overview, market shares, and growth opportunities of RDC (Radionuclide Drug Conjugate) Services market by product type, application, key players and key regions and countries.
Segmentation by Type:
Antibody Radionuclide Conjugates (ARC)
Peptide Radionuclide Conjugates (PRC)
Small Molecular Radionuclide Conjugates (SMRC)
Segmentation by Application:
Pharmaceutical Companies
Medical Device Companies
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Rdcthera
Abzena
WuXi XDC
CD Formulation
CPC Scientific Inc
Please note: The report will take approximately 2 business days to prepare and deliver.
RDC (Radionuclide Drug Conjugate) services refer to professional services provided for the development, production and application of radionuclide drug conjugates. These conjugates usually combine radioisotopes with drugs (such as monoclonal antibodies, peptides or small molecules) to target specific cells or tissues for treatment, especially in cancer treatment. The main contents of RDC services include drug development, radionuclide labeling and screening, preclinical research (evaluation of drug conjugates), etc.
United States market for RDC (Radionuclide Drug Conjugate) Services is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for RDC (Radionuclide Drug Conjugate) Services is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for RDC (Radionuclide Drug Conjugate) Services is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key RDC (Radionuclide Drug Conjugate) Services players cover Rdcthera, Abzena, WuXi XDC, CD Formulation, CPC Scientific Inc, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LPI (LP Information)' newest research report, the “RDC (Radionuclide Drug Conjugate) Services Industry Forecast” looks at past sales and reviews total world RDC (Radionuclide Drug Conjugate) Services sales in 2025, providing a comprehensive analysis by region and market sector of projected RDC (Radionuclide Drug Conjugate) Services sales for 2026 through 2032. With RDC (Radionuclide Drug Conjugate) Services sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world RDC (Radionuclide Drug Conjugate) Services industry.
This Insight Report provides a comprehensive analysis of the global RDC (Radionuclide Drug Conjugate) Services landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on RDC (Radionuclide Drug Conjugate) Services portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global RDC (Radionuclide Drug Conjugate) Services market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for RDC (Radionuclide Drug Conjugate) Services and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global RDC (Radionuclide Drug Conjugate) Services.
This report presents a comprehensive overview, market shares, and growth opportunities of RDC (Radionuclide Drug Conjugate) Services market by product type, application, key players and key regions and countries.
Segmentation by Type:
Antibody Radionuclide Conjugates (ARC)
Peptide Radionuclide Conjugates (PRC)
Small Molecular Radionuclide Conjugates (SMRC)
Segmentation by Application:
Pharmaceutical Companies
Medical Device Companies
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Rdcthera
Abzena
WuXi XDC
CD Formulation
CPC Scientific Inc
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
73 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 RDC (Radionuclide Drug Conjugate) Services Market Size by Player
- 4 RDC (Radionuclide Drug Conjugate) Services by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global RDC (Radionuclide Drug Conjugate) Services Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
